Cytek Biosciences to Showcase Advanced Spectral Flow Cytometry at Major Conferences

FREMONT, Calif., Sept. 03, 2026 /CourierPR/ -- Cytek Biosciences, a leader in spectral flow cytometry, is set to showcase its advanced technology at two major clinical cytometry conferences this fall, highlighting the growing importance of spectral flow cytometry in clinical research.

At the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference in Salzburg, Austria, from September 9 to 12, and at the 41st Annual International Clinical Cytometry Meeting & Course (ICCS) in Miami, Florida, from October 2 to 6, Cytek will demonstrate how its Full Spectrum Profiling™ (FSP®) technology enhances cell analysis capabilities and streamlines clinical workflows.

Cytek’s FSP technology, which captures the full spectrum of fluorescent signals, offers laboratories the ability to analyze more complex panels and improve data quality. With over 4,200 peer-reviewed publications citing Cytek’s FSP systems, the technology has become a cornerstone in fields such as cell biology, immunology, oncology, and clinical research.

At ESCCA, Cytek will host an Industrial Partner Presentation on September 11 at 12:15 p.m., titled “Do We Really Need 40 Colors? Rethinking Spectral Cytometry for Routine Diagnostics and MRD Monitoring.” The presentation will be led by Mikael Roussel, M.D., Ph.D., from the Hematology Laboratory & INSERM U1236 at University Hospital Pontchaillou. Roussel will discuss the role of spectral cytometry in routine diagnostics and minimal residual disease (MRD) monitoring.

Cytek will also exhibit at Booth PL2 during the conference, demonstrating the versatility of its spectral flow cytometry solutions in supporting sophisticated clinical applications. The company will host KOL dinners at both conferences to foster discussions on the evolving role of spectral flow cytometry in clinical laboratories.

At ICCS, Cytek will present at Booths 100/101 and host a Corporate Workshop on October 4 at 2:00 p.m. This workshop will further explore the applications of spectral flow cytometry in clinical research settings.

“Cytek is dedicated to advancing the adoption of spectral flow cytometry across the clinical research landscape,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “As the technology gains traction in clinical research, we are seeing new opportunities to expand its use in cell analysis workflows, including MRD research and other translational applications. Our goal is to help laboratories harness the power of spectral technology to generate more actionable insights while simplifying workflows and supporting better use of laboratory resources.”

Cytek’s FSP technology is part of its comprehensive suite of cell analysis solutions, which includes instruments, reagents, software, and services designed to meet the needs of research and clinical laboratories. The company’s products are available for research use only, with certain exceptions for clinical use in specific regions.